Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROVOCHOLINE vs ISOPTO CARPINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.
FDA: Diagnosis of bronchial airway hyperreactivity in subjects without clinically apparent asthma.,Off-label: Treatment of xerostomia, glaucoma.
FDA: For the treatment of elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.,Off-label: Emergency reduction of intraocular pressure in acute angle-closure glaucoma, induction of miosis during ocular surgery, diagnosis of Adie's tonic pupil.
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
Terminal elimination half-life is approximately 1.4 hours in healthy adults; clinically, this short half-life necessitates frequent dosing for sustained ocular effect.
Primarily metabolized by acetylcholinesterase.
Primarily metabolized by plasma esterases via hydrolysis, with some hepatic metabolism. Half-life ~1-2 hours. Excreted renally as metabolites and unchanged drug.
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is eliminated via urine within 24 hours, with about 20% as unchanged pilocarpine. Biliary/fecal elimination accounts for less than 5%.
Very low protein binding (<5%). Does not significantly bind to albumin or other plasma proteins.
Approximately 30% bound to plasma proteins, mainly albumin.
Approximately 0.1-0.2 L/kg. Small Vd indicates limited extravascular distribution, consistent with a quaternary ammonium compound that does not readily cross cell membranes or the blood-brain barrier.
Approximately 0.5 L/kg, indicating distribution largely into extracellular fluid; clinically, not extensively distributed to tissues.
Subcutaneous: approximately 90-100%. Oral: Very low (<2%) due to extensive presystemic metabolism by cholinesterases in the gastrointestinal tract and liver. Not administered orally. Inhalation: Variable, but effective locally; systemic absorption is minimal.
Ocular (topical): bioavailability is low due to nasolacrimal drainage and systemic absorption; exact % not well defined but systemic exposure is minimal with recommended ophthalmic dosing.
No specific guidelines; use caution in severe renal impairment.
No dosage adjustment required for renal impairment; drug is minimally systemically absorbed and renally eliminated.
No specific guidelines; use caution in severe hepatic impairment.
No dosage adjustment required for hepatic impairment; drug is minimally systemically absorbed and primarily metabolized locally.
Safety and efficacy not established; use not recommended.
Not recommended for use in children due to lack of safety and efficacy data; use only if potential benefit outweighs risk.
Use with caution due to potential for increased sensitivity and comorbidities; consider starting at lower end of dosing range.
Use with caution in elderly patients due to increased risk of systemic anticholinergic effects (e.g., bradycardia, bronchospasm); consider lower concentration or frequency.
Severe asthma or wheezing; administration to patients with asthma can cause fatal bronchospasm.
None
Should be administered only by trained personnel; emergency resuscitative equipment must be immediately available; may cause bronchoconstriction, bradycardia, hypotension; use caution in patients with cardiovascular disease, epilepsy, hyperthyroidism, peptic ulcer, urinary obstruction.
Risk of retinal detachment, especially in patients with pre-existing retinal disease or myopia.,May cause ciliary spasm, brow ache, and induced myopia.,Caution in patients with corneal abrasion or contact lens use due to miosis and accommodation effects.,Bronchospasm risk in patients with asthma or COPD.,Bradycardia, hypotension, and increased GI motility (use caution in peptic ulcer disease, urinary tract obstruction, or Parkinson's disease).,Systemic absorption can cause cholinergic toxicity.
Asthma, COPD, severe cardiac disease, recent myocardial infarction, hypotension, hypertension, hyperthyroidism, epilepsy, Parkinson's disease, peptic ulcer, gastrointestinal or urinary obstruction, pregnancy (Category C).
Hypersensitivity to pilocarpine or any component.,Acute iritis, acute anterior uveitis, or acute inflammatory conditions of the anterior chamber.,Narrow-angle glaucoma (unless considered for emergency treatment under specialist care).,Uncontrolled asthma, COPD, or other bronchospastic conditions.,Severe cardiovascular disease (bradycardia, hypotension, recent MI).,Gastrointestinal or urinary tract obstruction.,Concomitant use with other cholinergic agents due to additive toxicity.
Avoid caffeine-containing foods and beverages (coffee, tea, chocolate, cola) for at least 6 hours prior to bronchial challenge testing as they can affect airway reactivity.
No known food interactions.
Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, bronchial provocation testing is generally avoided during pregnancy due to potential maternal hypoxia and fetal distress. First trimester: theoretical risk from maternal hypoxia; second and third trimesters: risk of preterm labor and fetal hypoxia if severe bronchospasm occurs.
Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.
No human data on excretion in breast milk. Methacholine is rapidly hydrolyzed by plasma cholinesterases; systemic absorption after inhalation is minimal. M/P ratio is unknown. Caution is advised, but risk to nursing infant is likely low given rapid metabolism and low bioavailability.
Limited data; no M/P ratio available. Pilocarpine may suppress lactation via cholinergic effect. Use caution; monitor infant for cholinergic side effects.
No specific dosing adjustments are recommended for methacholine challenge testing during pregnancy; however, the test is typically deferred due to potential risks. If conducted, start with lowest concentration (0.025 mg/m L) and titrate cautiously with close monitoring due to possible increased sensitivity of airway receptors and altered pharmacokinetics (increased plasma volume and decreased cholinesterase activity may prolong effects).
No established dose adjustments. Monitor IOP closely; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Titrate to effect.
Provocholine (methacholine chloride) is used for bronchial challenge testing to diagnose airway hyperreactivity in patients with suspected asthma but normal baseline spirometry. Administer with a nebulizer in increasing concentrations (0.025 to 25 mg/m L). Contraindicated in patients with FEV1 < 60% predicted, recent myocardial infarction, severe hypertension, or known hypersensitivity. Emergency resuscitation equipment must be available. Monitor for bronchospasm, oxygen desaturation, and treat with short-acting beta-agonists if needed.
Isopto Carpine (pilocarpine ophthalmic solution) is a miotic agent used for glaucoma and ocular conditions. It causes miosis and ciliary muscle contraction, reducing intraocular pressure. Onset of miosis is 10–30 minutes, lasting 4–8 hours. Use with caution in patients with retinal detachment, asthma, or bradycardia. Systemic absorption can cause sweating and salivation.
This test measures how sensitive your airways are to a substance that can cause narrowing.,You will inhale increasing doses of methacholine through a nebulizer while your breathing is tested.,Inform your doctor if you have asthma, recent heart attack, high blood pressure, or are pregnant.,Do not use caffeine or tobacco for at least 6 hours before the test.,Avoid using inhaler medications (e.g., albuterol) for 8-12 hours before the test as directed.,You may experience coughing, chest tightness, or shortness of breath during the test.,The test is stopped if your breathing drops significantly, and medication will be given to reverse effects.
Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1–2 minutes after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait at least 15 minutes before reinserting.,May cause blurred vision, especially at night; avoid driving until vision clears.,Use caution in low-light conditions due to miosis.
"The serum concentration of Bupropion can be increased when it is combined with Choline."
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline."
"The serum concentration of Choline can be increased when it is combined with Tipiracil."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROVOCHOLINE vs ISOPTO CARPINE, answered by our medical review team.
PROVOCHOLINE is a Cholinergic Agonist that works by Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.. ISOPTO CARPINE is a Ophthalmic Cholinergic Agonist that works by Pilocarpine, a direct-acting cholinergic agonist, stimulates muscarinic receptors (M3 subtype) in the ciliary muscle and iris sphincter muscle, causing miosis and contraction of the ciliary muscle. This opens the trabecular meshwork and increases aqueous humor outflow facility, reducing intraocular pressure in glaucoma. Also induces accommodation spasm.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROVOCHOLINE and ISOPTO CARPINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROVOCHOLINE is: Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.. The standard adult dose of ISOPTO CARPINE is: 1 to 2 drops of a 1% to 4% solution in the affected eye(s) up to 4 times daily, as needed to reduce intraocular pressure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROVOCHOLINE and ISOPTO CARPINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROVOCHOLINE is classified as Category C. Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, b. ISOPTO CARPINE is classified as Category C. Insufficient human data. Animal studies: no teratogenicity at ocular doses. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.